오스트레일리아 - 영어 - APVMA (Australian Pesticides and Veterinary Medicines Authority)

ceva animal health pty ltd - mepivacaine hydrochloride - parenteral liquid/solution/suspension - mepivacaine hydrochloride caine active 20.0 mg/ml - anaesthetics/analgesics - horse | colt | donkey | endurance horse | filly | foal | gelding | high performance horses | horses at stud | mare | pacer | pol - anaesthetic - local/general | general anaesthetic | immobiliser | local anaesthetic | premedication | sedative | tranquilliser | travel sickness

아일랜드 - 영어 - HPRA (Health Products Regulatory Authority)

boc gases ireland ltd - oxygen - medicinal gas, cryogenic - 99.5 percent volume/volume - medical gases; oxygen

아일랜드 - 영어 - HPRA (Health Products Regulatory Authority)

air products ireland limited - oxygen - inhalation gas - min 99.5 %v/v - medical gases

아일랜드 - 영어 - HPRA (Health Products Regulatory Authority)

industrial pressure testing ltd - oxygen - inhalation gas - 100 %v/v - oxygen - it is used in the treatment of: acute severe asthma, pulmonary thrombo-embolism, pneumonia and fibrosing alveolitis, carbon monoxide poisoning, pulmonary oedema and as a diluent or carrier gas in anaesthesia.

몰타 - 영어 - Malta Medicines Authority

1 a pharma gmbh keltenring 1+3, 82041 oberhaching, germany - rivastigmine - transdermal system - rivastigmine 9 mg - psychoanaleptics

몰타 - 영어 - Malta Medicines Authority

1 a pharma gmbh keltenring 1+3, 82041 oberhaching, germany - rivastigmine - transdermal system - rivastigmine 18 mg - psychoanaleptics

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - buprenorphine, quantity: 5 mg - drug delivery system, transdermal - excipient ingredients: levulinic acid; oleyl oleate; povidone; polyethylene; ethyl acetate; 2-ethylhexyl acrylate; vinyl acetate; butyl acrylate; acrylic acid; 2,2'-azobisisobutyronitrile; aluminium acetylacetonate; heptane; acrylates copolymer; ethylene distearamide; adipic acid/1,4-butanediol/mdi copolymer; pentaerythrityl tetra-di-t-butyl hydroxyhydrocinnamate - buprenorphine sandoz patches are indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment. buprenorphine sandoz patches are not indicated for use in chronic non-cancer pain other than in exceptional circumstances. buprenorphine sandoz patches are not indicated as an as-needed (prn) analgesia.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - buprenorphine, quantity: 20 mg - drug delivery system, transdermal - excipient ingredients: povidone; oleyl oleate; polyethylene; levulinic acid; ethyl acetate; 2-ethylhexyl acrylate; vinyl acetate; butyl acrylate; acrylic acid; 2,2'-azobisisobutyronitrile; aluminium acetylacetonate; heptane; acrylates copolymer; ethylene distearamide; adipic acid/1,4-butanediol/mdi copolymer; pentaerythrityl tetra-di-t-butyl hydroxyhydrocinnamate - buprenorphine sandoz patches are indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment. buprenorphine sandoz patches are not indicated for use in chronic non-cancer pain other than in exceptional circumstances. buprenorphine sandoz patches are not indicated as an as-needed (prn) analgesia.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - buprenorphine, quantity: 15 mg - drug delivery system, transdermal - excipient ingredients: povidone; polyethylene; levulinic acid; oleyl oleate; ethyl acetate; 2-ethylhexyl acrylate; vinyl acetate; butyl acrylate; acrylic acid; 2,2'-azobisisobutyronitrile; aluminium acetylacetonate; heptane; acrylates copolymer; ethylene distearamide; adipic acid/1,4-butanediol/mdi copolymer; pentaerythrityl tetra-di-t-butyl hydroxyhydrocinnamate - buprenorphine sandoz patches are indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment. buprenorphine sandoz patches are not indicated for use in chronic non-cancer pain other than in exceptional circumstances. buprenorphine sandoz patches are not indicated as an as-needed (prn) analgesia.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - buprenorphine, quantity: 10 mg - drug delivery system, transdermal - excipient ingredients: povidone; polyethylene; levulinic acid; oleyl oleate; ethyl acetate; 2-ethylhexyl acrylate; vinyl acetate; butyl acrylate; acrylic acid; 2,2'-azobisisobutyronitrile; aluminium acetylacetonate; heptane; acrylates copolymer; ethylene distearamide; adipic acid/1,4-butanediol/mdi copolymer; pentaerythrityl tetra-di-t-butyl hydroxyhydrocinnamate - buprenorphine sandoz patches are indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment. buprenorphine sandoz patches are not indicated for use in chronic non-cancer pain other than in exceptional circumstances. buprenorphine sandoz patches are not indicated as an as-needed (prn) analgesia.